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Abstract
Context: Post-finasteride syndrome (PFS) occurs in patients with androgenic alopecia 
after suspension of the finasteride treatment, leading to a large variety of persistent side 
effects. Despite the severity of the clinical picture, the mechanism underlying the PFS 
symptoms onset and persistence is still unclear.
Objective: To study whether epigenetic modifications occur in PFS patients.
Methods: Retrospective analysis of a multicentric, prospective, longitudinal, case–control 
clinical trial, enrolling 16 PFS patients, compared to 20 age-matched healthy men. Main 
outcomes were methylation pattern of SRD5A1 and SRD5A2 promoters and concentration 
of 11 neuroactive steroids, measured by liquid chromatography-tandem mass 
spectrometry, in blood and cerebrospinal fluid (CSF) samples.
Results: SRD5A1 and SRD5A2 methylation analysis was performed in all blood samples 
(n = 16 PFS patients and n = 20 controls), in 16 CSF samples from PFS patients and in 
13 CSF samples from controls. The SRD5A2 promoter was more frequently methylated 
in CSF of PFS patients compared to controls (56.3 vs 7.7%). No promoter methylation 
was detected in blood samples in both groups. No methylation occurred in the SRD5A1 
promoter of both groups. Unmethylated controls compared to unmethylated SRD5A2 
patients showed higher pregnenolone, dihydrotestosterone and dihydroprogesterone, 
together with lower testosterone CSF levels. Andrological and neurological assessments 
did not differ between methylated and unmethylated subjects.
Conclusions: For the first time, we demonstrate a tissue-specific methylation pattern of 
SRD5A2 promoter in PFS patients. Although we cannot conclude whether this pattern is 
prenatally established or induced by finasteride treatment, it could represent an important 
mechanism of neuroactive steroid levels and behavioural disturbances previously 
described in PFS.
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Introduction
Finasteride is an inhibitor of 5 alpha-reductase (5α-R) type 
1 and 2 enzymes, encoded by the SRD5A1 and SRD5A2 
gene, respectively, with higher affinity for 5α-R type 2 
in the human (1, 2). This enzyme converts testosterone 
into dihydrotestosterone (DHT) and progesterone into 
dihydroprogesterone (DHP) (3).
Clinically, finasteride is used to control the 
progression of benign prostatic hyperplasia and of 
androgenetic alopecia. Albeit being a well-tolerated and 
relatively safe drug, recent clinical studies showed sexual 
adverse effects (2, 4, 5, 6, 7). Interestingly, a small subset 
of patients using finasteride for androgenic alopecia, 
complains of persistent sexual side effects during and 
even after discontinuation of the treatment (2, 8, 9, 10, 
11, 12, 13, 14, 15, 16, 17, 18, 19, 20). Beside adverse 
events in the sexual sphere, some patients interrupting 
the treatment by finasteride develop depression (16, 17, 
18, 20, 21, 22, 23), reduction in self-confidence, decreased 
initiative and difficulty in concentration, forgetfulness or 
loss of short-term memory, irritability, suicidal thoughts, 
anxiety, panic attack, sleep problems, muscular stiffness 
and cramps, tremors, chronic fatigue, joint pain and 
muscular ache (18, 24, 25, 26). These various symptoms 
amount to the so-called post-finasteride syndrome (PFS). 
Two recent clinical studies objectivated impaired sexual 
function and major depression in PSF patients (17, 18). In 
addition, functional magnetic resonance imaging (MRI) 
showed abnormalities in the brain regions implicated 
in depression and regulating sexual arousal (17), and 
some evidence of neuropathy involving the peripheral 
neurogenic control of erection was produced (18).
PFS etiopathogenesis remains elusive. Three different 
clinical studies (18, 25, 26) demonstrated that finasteride 
treatment not only affects the steroids directly related 
with the enzyme 5α-R but has broad consequences on 
the levels of several important physiological regulators of 
the nervous function, such as neuroactive steroids, both 
in plasma and in cerebrospinal fluid (CSF). These results 
were confirmed in an animal model of PFS, showing 
that alterations in the levels of neuroactive steroids not 
only occurred in plasma and CSF but also in brain areas, 
such as cerebral cortex, cerebellum and hippocampus 
(27), associated to depressive-like behaviour, alterations 
in neurogenesis, gliosis, neuroinflammation and gut 
microbiota composition (28). A possible hypothesis for 
the persistent side effects may be epigenetic modifications 
occurring in PFS patients. Indeed, downregulation and 
hypermethylation of 5α-R were observed in the rodent 
nervous system and associated with inflammation and 
depression (29, 30), features that, as mentioned earlier, 
have been also observed in PFS model (28). In this setting, 
the evaluation of the methylation pattern remains 
challenging since it could change during adulthood and 
with ageing (31).
In this study, we hypothesised that inappropriate 
methylation of SRD5A1 and/or SRD5A2 gene promoters 
could be present in the central nervous system (CNS) 
of patients with PFS. No studies evaluated so far the 
methylation levels of these genes in a clinical setting. We 
compared SRD5A1 and/or SRD5A2 promoter methylation 
in DNA samples obtained from blood and/or CSF in 
PFS patients and controls and correlated the resulting 
epigenetic pattern with the neuroactive steroid levels 
previously found by us to be associated with major 
depression and sexual side effects (18).
Materials and methods
Study design and sample preparation
Sixteen patients affected by PFS, recruited through 
the ‘Italian network of finasteride side effects’, were 
included in this study. They were otherwise healthy men, 
aged 22–44  years, who reported persistent sexual and 
mental health side effects after the use of 1–1.25 mg of 
finasteride daily (Propecia, Proscar or generic finasteride) 
for androgenetic alopecia. Only subjects who had 
discontinued finasteride at least 3  months earlier were 
included. The study procedure was approved by the 
Ethics Committee of the San Gerardo Hospital (approval 
n.142/2012), Monza-Italy and the participating subjects 
provided their written informed consent before enrolment. 
This group of PFS patients was previously studied for 
psychiatric components, andrological assessment and 
neuroactive steroid levels in plasma and CSF (18).
PFS patients underwent both blood and CSF sampling 
for SRDA51 and SRDA52 gene promoter methylation 
analysis. The control group included 18 healthy 
individuals who underwent spinal anaesthesia for 
planned orthopaedic surgery of the lower limb at the San 
Gerardo Hospital of Monza. These subjects were otherwise 
healthy and never made used of finasteride. After written 
informed consent, CSF samples were collected. Two 
subjects of this group provided also a blood sample for 
DNA analysis. Moreover, the control group included 
additional 18 age-matched healthy donors, who provided 
only blood samples for DNA analysis. Control subjects 
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never used finasteride. The mean age of healthy controls 
(40.8 ± 17.9 years) was not significantly different from PFS 
patients (34.5 ± 8.8 years) (P = 0.192).
SRD5A1 and SRD5A2 promoter sequences
Sequences of SRD5A1 and SRD5A2 gene promoters served 
for designing primer probes to be used for methylation 
analysis. SRD5A1 and SRD5A2 promoter sequences were 
obtained by the online Eukaryotic Promoter Database 
(EPD; http://epd.vital-it.ch) and correspond to the 
database ID ‘SRD5A1_1’ and ‘SRD5A2_1’, respectively. The 
SRD5A2 promoter sequence was previously described (32) 
and matched to that obtained by the EPD, confirming its 
reliability.
DNA extraction and methylation analysis
Genomic DNA was isolated from blood and CSF samples 
by the automated extractor EZ1 Advanced XL (Qiagen) 
using the EZ1 DNA Blood and the EZ1 DNA Investigator 
Kits, respectively. We assumed that ependymal cells, 
of neuroectodermic origin and collected from CSF, are 
representative of the CNS, providing a source of genomic 
DNA without resorting to major clinical interventions. 
Due to the paucity of the cellular component in the CSF, 
DNA extraction was preliminarily validated, using a kit 
optimised for forensic purposes, to provide a yield of at 
least 2.8 ± 1.1 ng/µL from 4.3 ± 3.3 cells/µL (data obtained 
from four random, anonymised, sterile CSF validation 
samples, ranging from 100 to 500 µl of total volume).
DNA concentrations and purity were determined by 
the NanoDrop™ 2000 spectrophotometer (Thermo Fisher 
Scientific), while the methylation pattern was analysed 
using the Human Methylated & Non-methylated DNA 
Set (Zimo Research, Irvine, CA, USA). Serial dilutions 
of methylated DNA (0–100% range), provided by the 
supplier, were performed to generate the standard curve. 
Deamination of cytosines was obtained by bisulfite 
conversion of equal amounts of DNAs using the Methylamp 
DNA Modification Kit (EpiGentek, Farmingdale, NY, 
USA) and following the instructions provided by the 
Company. Quantitative methylation-specific PCR 
(Q-MSP) was performed for methylation analysis of CpG 
islands of SRD5A1 and SRD5A2 promoter regions. The 
methylation-specific primer pairs were designed by the 
MethPrimers Software (33) as follows: SRD5A1 forward 
(Fwd): 5′-AGTTTTATATTTTTCGGGATTTTCG-3′ and 
reverse (Rev): 5′-CGCTTTAAACTTATTCCTAAACGAT-3′; 
SRD5A2 Fwd: 5′-AAGTTATGGAAGGATAGTTTAAGCG-3′ 
and Rev: 5′-TCTCAAAAATACAACCGCGAT-3′. The 
methylation-specific primers for the ACTB gene were 
previously validated (34) and used to provide the internal 
control. Reactions were performed using the Precision 
Melt Supermix (Bio-Rad Laboratories Inc.) following the 
supplier’s instructions and following settings: double-
strand DNAs were pre-denatured 2 min at 95°C before 50 
cycles of DNA denaturation at 95°C for 10 s, each followed 
by primer binding at 59°C for 30 s and extension at 72°C 
for 30 s. Samples and the standard curve were analysed 
in duplicate and the percentage of DNA methylation was 
calculated using the previously described 2−ΔΔCt method 
(35) optimised for DNA methylation analyses (36, 37). 
Briefly, ΔCt values were calculated by subtracting the 
internal control Ct value to Ct of samples and standards. 
ΔΔCt was determined by subtracting the ΔCt of the 
100% methylated DNA standard to the ΔCt of samples 
and standard dilutions. Standards were plotted on a X-Y 
graph, where the percentage of methylated DNA is at 
the X axis, while the 2−ΔΔCt value is at the Y axis. These 
data were interpolated by linear regression and used for 
extrapolating the percentage of sample DNA methylation.
Precision of the DNA methylation assay
Precision of the method was assessed by evaluating the 
coefficient of variation (%CV) (38) in relationship to 
the percentage of methylation. To this purpose, DNA 
with known percentages of methylation were created by 
serial dilution as reference standard and the coefficient of 
variation was calculated as the standard deviation divided 
by the mean (×100).
Cut-off for defining the methylated status was fixed 
at 10% and values below this threshold were considered 
as unmethylated DNA, as previously proposed (39). %CV 
of each sample was extrapolated from the reference 
standard curve and used for evaluating whether it was 
reliably determined as falling above the methylation cut-
off value. All samples are reliably classified as ‘methylated’ 
or ‘unmethylated’, according to the cut-off value fixed at 
10% CV.
Statistical analysis
Results are expressed as mean ± s.d. Methylation status of 
the SRD5A1 and SRD5A2 gene promoters were expressed 
as percentage of methylated DNA extrapolated from the 
standard curve.
Kolmogorov–Smirnov test was used to evaluate 
continuous neuroactive steroid data distribution. 
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Neuroactive steroid levels in plasma and CSF previously 
obtained (18) were compared between SRD5A2 
unmethylated controls, methylated and unmethylated 
PFS patients using Kruskall–Wallis test followed by post hoc 
Dunnet test. The correlation between neuroactive steroid 
levels and percentage of promoter gene methylation was 
evaluated using Spearman’s Rho test.
The degree of erectile dysfunction and the depressive 
status of PSF patients was previously reported (18) and was 
reassessed here by comparing SRD5A2 unmethylated and 
methylated PFS patients using Pearson’s chi-squared test. 
Similarly, the total score of Beck Depression and Anxiety 
Inventories (BDI, BAI) and K-10 was compared between 
patients with and without SRD5A2 methylation, using 
Mann–Whitney’s U test.
Statistics was performed using ‘Statistical Package for 
the Social Sciences’ software for Macintosh (version 20.0; 
SPSS Inc.).
Results
DNA methylation analysis of SRD5A1 and SRD5A2 was 
successfully performed in all blood samples (n = 16 PFS 
patients and n = 20 controls), in 16 CSF samples from PFS 
patients and in 13 CSF samples from controls.
The SRD5A1 gene promoter was completely 
unmethylated in all samples analysed, irrespective 
whether blood- or CSF-derived DNA.
Similarly, the SRD5A2 gene promoter resulted 
unmethylated (i.e. methylation level <10%) in all blood-
derived DNA samples, both in controls and in PFS patients. 
In CSF-derived DNA, the SRD5A2 gene promoter resulted 
methylated in 9 out of 16 PFS patients and in 1 out of 
13 controls (P = 0.006, Pearson’s chi-square test, Table 1). 
Interestingly, the control subject with positive CSF 
SRD5A2 methylation was a man affected by normotensive 
hydrocephalus. In the PFS patients with positive SRD5A2 
methylation in CSF, the methylation levels ranged from 
15.4 to 100% (mean: 40.3%, median: 31.8%), while the 
unique control sample resulted to be positive to the test 
showed 58.0% methylation.
Neuroactive steroid levels in these subjects were 
reported previously (18). In order to assess whether 
SRD5A2 methylation affects neuroactive steroid levels, 
here we compared CSF concentrations in unmethylated 
controls vs unmethylated and methylated PFS patients 
(Table  2). Within the limits of the low subject number 
and of the sensitivity of the LC-MS/MS method for some 
analytes, the results showed some statistically significant 
differences (Table  2) indicating higher pregnenolone in 
unmethylated SRD5A2 controls vs unmethylated SRD5A2 
PFS patients. On the contrary, higher testosterone levels 
were reported in unmethylated SRD5A2 PFS patients 
vs unmethylated SRD5A2 controls. The 5α-reduced 
metabolites of testosterone and progesterone were also 
affected. In particular, higher DHT levels were observed in 
unmethylated SRD5A2 controls vs unmethylated SRD5A2 
PFS patients (Table  2). In addition, DHP levels were 
significantly higher in unmethylated SRD5A2 controls 
not only vs unmethylated SRD5A2 PSF patients but also 
vs methylated SRD5A2 PSF patients (Table 2).
In PFS patients, neuroactive steroid CSF levels were 
not significantly related to the percentage of SRD5A2 gene 
promoter methylation (P > 0.05, Spearman’s Rho test).
We next evaluated whether the clinical parameters 
reported earlier (18) were related to the SRD5A2 
methylation status. No differences were observed in the 
degree of erectile dysfunction (P = 0.362, Pearson’s chi-
square test). Accordingly, the five international indexes of 
erectile function (IIEF-15) domains, identified as erectile 
function, orgasm, sexual desire, intercourse satisfaction 
and overall satisfaction, did not differ between groups 
(P = 0.710, P = 0.456, P = 0.535, P = 0.805 and P = 0.620, 
respectively). Similarly, the depressive status previously 
demonstrated in these PFS patients (18) did not change 
between SRD5A2 methylated and unmethylated subjects, 
considering K-10 (P = 0.890) and BDI and BAI (P = 0.475 
and P = 0.485, respectively). The depression and anxiety 
degree frequency did not change between two groups 
(P = 0.270 and P = 0.176, respectively).
Discussion
In this study, we demonstrate that SRD5A2 promoter 
methylation in PFS patients is different between tissues 
of neuroectodermic and mesodermic origin. Although 
DNA extraction was insufficient in five CSF samples, a 
significant difference between PFS patients and controls 
Table 1 SRD5A2 promoter methylation in DNA extracted 
from cerebrospinal fluid of PFS patients and controls.
Controls (n) PFS patients (n) Total (n)
Unmethylated 
SRD5A2
12 (92.3%) 7 (43.7%) 19
Methylated SRD5A2 1 (7.7%) 9 (56.3%) 10
Total (n) 13 16
Data were evaluated by Pearson’s chi-square test, P < 0.01.
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in SRD5A2 promoter methylation of nervous system (i.e., 
in CSF) was demonstrated, while no differences were 
seen for the SRD5A1 gene, which resulted unmethylated 
in all samples analysed. Interestingly, in PFS patients, 
SRD5A2 methylation was detected in CSF DNA samples 
in 56% of the cases, while it was absent in blood DNA, 
demonstrating a tissue-specific epigenetic gene silencing. 
The only CSF sample showing SRD5A2 methylation in 
controls was detected in one man with normotensive 
hydrocephalus. Methylation in CSF but not in blood 
may be not surprising, since methylation is a tissue- and 
cell-specific process (40, 41, 42). The low number of cases 
studied here does not allow definitive conclusions, but we 
can speculate that PFS primarily affects nervous system via 
methylation of SRD5A2, which, in turn, may be related to 
the clinical picture of PFS patients (i.e., major depression 
and evidence of neuropathy involving the peripheral 
neurogenic control of erection) (18, 43).
In this context, it is important to note that in 
human prostate, methylation of SRD5A2 is regulated 
by DNA methyltransferase 1 (DNMT1) (44) and that, as 
demonstrated in animal models, forebrain deletion of 
DNMT1 (45) or its pharmacological inhibition (44, 46) 
had antidepressant-like properties.
The reason for the persistence of PFS symptoms even 
long after drug withdrawal in PFS patients remains a 
mystery. The molecular mechanism of 5α-R inactivation 
by finasteride is known since two decades (47), likely 
resulting in persistent enzymatic inhibition over time 
(47, 48), but this does not fully justify the long-lasting 
alteration of the neuroactive steroid levels, unless several 
months/years are required to completely wash-out 
the drug from the CSF. Assuming that the 5α-R protein 
blocked by finasteride cannot become functional again, in 
this study, we hypothesised that new SRD5A1 and SRD5A2 
transcripts should be produced and new 5α-R protein 
should be available once the drug is interrupted, provided 
the gene promoters are not methylated and silenced. This 
should be evident from the CSF steroid concentrations in 
relation to the methylation pattern. Significant changes 
in neuroactive steroid levels in this group of PFS patients 
were published earlier, demonstrating a derangement 
of these levels upstream testosterone production (18). 
In fact, PFS patients showed higher serum and CSF 
testosterone levels than healthy controls, while other 
neuroactive steroids, also including DHT, were suppressed 
(18). In the present study, the comparison of CSF steroid 
levels subdividing the patients according to their SRD5A2 
methylation status provided some further insights. In 
unmethylated SRD5A2 PFS patients, we can assume that 
type 2 5α-R is regularly expressed in CNS and finasteride 
can act on it. Indeed, in these patients the blockade 
of 5α-R activity by finasteride results in significant 
accumulation of testosterone and significant reduction 
of 5α-reduced metabolites DHT and DHP, the latter 
being even undetectable (Table 2). On the other hand, in 
methylated SRD5A2 patients, finasteride might act, even 
if with lower affinity, predominantly or only on the type 1 
5α-R, since SRD5A1 should be expressed. This is suggested 
by the only partial reduction of DHP, while testosterone 
and DHT levels were not significantly different from 
controls. The significant decrease in pregnenolone 
in SRD5A2 unmethylated PFS patients compared to 
controls indicate that the blockade of type 2 5α-R activity 
impacts the very early steps of neurosteroidogenesis 
as well, although with unknown mechanism. 
Table 2 Neuroactive steroid CSF levels in patients and controls according to the SRD5A2 methylation status.
Unmethylated SRD5A2 
controls (n = 12)
Unmethylated SRD5A2 PFS 
patients (n = 7)
Methylated SRD5A2 PFS 
patients (n = 9) P value
Pregnenolone 0.39 ± 0.25 0.09 ± 0.05a 0.31 ± 0.46 0.008
Progesterone 0.11 ± 0.14 0.05 ± 0.01 0.34 ± 0.82 0.111
Dihydroprogesterone 3.07 ± 1.54 0.25 ± 0.00a,b 1.00 ± 1.28a 0.001
Isopregnanolone 0.11 ± 0.03 0.10 ± 0.00# 0.32 ± 0.63 0.531
Tetrahydroprogesterone 0.11 ± 0.03 0.25 ± 0.29 0.10 ± 0.00b 0.275
Dehydroepiandrosterone 0.29 ± 0.08 0.33 ± 0.05 0.51 ± 0.58 0.217
Testosterone 0.23 ± 0.85 2.53 ± 2.35a 1.26 ± 1.48 0.028
Dihydrotestosterone 0.15 ± 0.12 0.05 ± 0.01a 0.49 ± 1.13 0.029
3α-Diol 0.05 ± 0.00# 0.07 ± 0.04 0.64 ± 0.86 0.081
3β-Diol 0.05 ± 0.00# 0.05 ± 0.00b 0.25 ± 0.57 0.305
17β-Estradiol 0.4 ± 0.06 0.02 ± 0.00b 0.22 ± 0.56 0.676
Neuroactive steroid levels were previously reported (18). Detection limit was 0.1 pg/µL for isopregnanolone and tetrahydroprogesterone, 0.05 pg/µL for 
progesterone, and 3β-diol, 0.02 pg/µL for 17β-estradiol. Data are expressed as pg/µL (mean ± s.d.). Data were analysed by Kruskall–Wallis test followed by 
post hoc Dunnet test (a vs unmethylated controls, P < 0.05). Bold indicates statistical significance.
bDenotes analytes for which the assay detection limit was used for the statistical analysis.
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These results, however, must be interpreted with 
extreme caution, given the low number of subjects 
analysed. In animal models, it was demonstrated 
that neurosteroidogenesis may proceed in the brain 
converting progesterone in DHP and further into 
tetrahydroprogesterone (THP; allopregnanolone) (3) via 
a pathway similar to the so-called backdoor pathway 
of 5α-reduction, using type 1 5α-R (49). Therefore, the 
changes in neuroactive steroid levels in CSF of PFS patients 
demonstrated earlier (18), might be due to inhibition 
of type 2 5α-R only in the subjects with unmethylated 
SRD5A2, while in those with methylated SRD5A2, type 
1 5α-R could be the target of finasteride. Whether the 
sexual and psychiatric symptoms documented in these 
patients are related to methylation of SRD5A2 cannot 
be concluded by this study, as no significant differences 
could be demonstrated in dependence thereof, probably 
due to the low number of subjects.
Presently, it is impossible to establish whether the 
SRD5A2 methylation pattern in PFS patients is set during 
early embryo development or results from finasteride 
treatment itself. DNA methylation is imprinted during 
gamete production and reprogrammed before embryo 
implantation (50). Besides the role in determining tissue-
specific gene expression, epigenetic mechanisms regulate 
the individual-specific differentiation of pluripotent stem 
cells into neurons, suggesting that methylation impacts 
the pathogenesis of psychiatric disorders (51). Recent 
findings in rat models confirmed that altered epigenetic 
processes, consisting in abnormal DNA methyltransferase 
protein levels and increased global DNA methylation 
levels, are linked to anxiety- and depression-like behaviour 
(52). Our finding of high levels of methylated SRD5A2 in 
CNS cells of a normotensive hydrocephalus individual, 
displaying an epigenetic status at odds with all other 
control subjects, further supports the link between DNA 
methylation pattern and disorders of the nervous system 
(53). If abnormal SRD5A2 promoter methylation is 
established prenatally, these subjects could be predisposed 
to develop the PFS and alteration of neuroactive steroid 
levels in the brain. In this case, treatment by finasteride 
might precipitate a dormant depressive phenotype linked 
to such specific epigenetic pattern, resulting in the clinical 
picture described previously (18, 43). Before finasteride 
treatment, the impairment of 5α-R type 2 in the nervous 
system would be partly compensated by the activity of 
the 5α-R type 1, found always unmethylated and thereby 
expressed. On the other hand, the native DNA methylation 
pattern may change during adulthood and it is susceptible 
to ageing (54, 55), diseases (56, 57, 58, 59), environmental 
factors and inflammation (60, 61). Most importantly, 
similar effects might be triggered by prolonged exposure to 
certain drugs, such as amphetamine and methamphetamine 
(62), inducing behavioural abnormalities. We cannot 
exclude that some SRD5A2 promoter methylation is 
determined by finasteride (or other drugs) exposure in 
adulthood in some subjects developing PFS, although the 
mechanism of such predisposition remains obscure. Given 
that epigenetic programming impacts the neuroendocrine 
response during the adult life (63), we could hypothesise 
that finasteride impairs DNA methylation targeted to 
the nervous system, leading to altered neurosteroid CSF 
levels and leading to major depression and neuropathy 
described in PFS patients (18, 43), but this remains 
highly speculative.
In conclusion, our results demonstrate methylation 
of SRD5A2 promoter in a tissue-specific manner in PFS 
patients. Whether this epigenetic pattern is established 
prenatally or induced by finasteride treatment cannot be 
concluded but this study pinpoints the relevance of this 
specific methylation pattern and its correlation with levels 
of neuroactive steroids and their effects (18, 43). Animal 
models might be useful to elucidate the link between the 
use of finasteride, epigenetic changes, neuroactive steroid 
levels and behavioural disturbances described previously 
in PFS patients (27, 28).
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